Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937105 | 0.95 | IGF1R (0.69) | IGF1RXIAPHSD11B1KMT2AMEN1 | |
| SCHEMBL2937103 | 0.95 | IGF1R (0.69) | IGF1RXIAPHSD11B1KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL3739554 | 0.89 | IGF1R (0.69) | IGF1RHSD11B1PTGDR2KMT2AMAPK1 | |
| Trifluoroacetic Acid SCHEMBL3723547 | 0.88 | IGF1R (0.46) | IGF1RPTGDR2KMT2AMEN1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL3726914 | 0.87 | IGF1R (0.66) | IGF1RXIAPHSD11B1PTGDR2KMT2A | |
| Trifluoroacetic Acid SCHEMBL2935701 | 0.86 | IGF1R (0.65) | IGF1RXIAPHSD11B1PTGDR2KMT2A | |
| Trifluoroacetic Acid SCHEMBL3724562 | 0.86 | IGF1R (0.65) | IGF1RXIAPHSD11B1PTGDR2KMT2A | |
| SCHEMBL2931273 | 0.85 | IGF1R (0.74) | IGF1RHSD11B1PTGDR2KMT2AMAPK1 | |
| SCHEMBL2931269 | 0.85 | IGF1R (0.74) | IGF1RHSD11B1PTGDR2KMT2AMAPK1 | |
| Trifluoroacetic Acid SCHEMBL3729731 | 0.85 | IGF1R (0.69) | IGF1RXIAPHSD11B1PTGDR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | IGF1R 306/4885XIAP 3196/4885HSD11B1 4844/4885 |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | IGF1R 1595/4885XIAP 1329/4885HSD11B1 2991/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | IGF1R 962/4885XIAP 1748/4885HSD11B1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.